高效编辑异常剪接位点恢复β-地中海贫血的β-珠蛋白表达
研究针对β-地中海贫血患者CD34+造血干/祖细胞,利用Cas9核糖核蛋白靶向IVS1-110G>A突变、Cas12a/Cpf1核糖核蛋白靶向IVS2-654C>T突变,实现高效治疗性编辑。编辑后红系后代异常剪接逆转、β-珠蛋白表达恢复,该策略有望用现有基因编辑技术纠正相当部分输血依赖型β-地中海贫血基因型。
要点
- 等位基因破坏异常剪接位点是恢复基因功能的稳健策略。
- Cas9与Cas12a/Cpf1核糖核蛋白在患者造血干/祖细胞中实现高效治疗性编辑。
- 编辑后红系后代异常剪接逆转、β-珠蛋白表达恢复。
核心结论
- 等位基因破坏异常剪接位点可恢复基因功能,该策略有望用现有基因编辑技术纠正相当部分输血依赖型β-地中海贫血基因型。
研究设计与样本
- 在β-地中海贫血患者原代CD34+造血干/祖细胞中,用Cas9核糖核蛋白靶向IVS1-110G>A突变,用Cas12a/Cpf1核糖核蛋白靶向IVS2-654C>T突变。
主要发现
- 每种核酸酶复合物均实现高编辑效率和高治疗性编辑穿透率。
- 编辑后患者造血干/祖细胞的红系后代异常剪接逆转、β-珠蛋白表达恢复。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The thalassemias are compelling targets for therapeutic genome editing in part because monoallelic correction of a subset of hematopoietic stem cells (HSCs) would be sufficient for enduring disease amelioration. A primary challenge is the development of efficient repair strategies that are effective in HSCs. Here, we demonstrate that allelic disruption of aberrant splice sites, one of the major classes of thalassemia mutations, is a robust approach to restore gene function. We target the IVS1-110G>A mutation using Cas9 ribonucleoprotein (RNP) and the IVS2-654C>T mutation by Cas12a/Cpf1 RNP in primary CD34+ hematopoietic stem and progenitor cells (HSPCs) from β-thalassemia patients. Each of these nuclease complexes achieves high efficiency and penetrance of therapeutic edits. Erythroid progeny of edited patient HSPCs show reversal of aberrant splicing and restoration of β-globin expression. This strategy could enable correction of a substantial fraction of transfusion-dependent β-thalassemia genotypes with currently available gene-editing technology.
引用
- Xu S, Luk K, Yao Q, et al. Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia. Blood. 2019. PMID: 30704988. doi:10.1182/blood-2019-01-895094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。